Clinical Trial Update: VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies. [Phase 4]

View source ↗

Summary

Phase 4 trial updating viral shedding results for VALTREX (valacyclovir) in HSV-2 seropositive subjects; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes
• Herpes Simplex Virus Infection

Drugs mentioned

• VALTREX (valacyclovir hydrochloride)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Herpesviridae | Phase 4 | Status: COMPLETED | Results posted: 2018-02-12